Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer

Costantino Mangioni, Giorgio Bolis, Nicola Natale, Luciano Morasca

Research output: Contribution to journalArticle

Abstract

A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented Müllerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.

Original languageEnglish
Pages (from-to)353-356
Number of pages4
JournalEuropean Journal of Cancer (1965)
Volume12
Issue number5
DOIs
Publication statusPublished - 1976

Fingerprint

Ovarian Neoplasms
Cyclophosphamide
Survival
Drug-Related Side Effects and Adverse Reactions
Therapeutics
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer. / Mangioni, Costantino; Bolis, Giorgio; Natale, Nicola; Morasca, Luciano.

In: European Journal of Cancer (1965), Vol. 12, No. 5, 1976, p. 353-356.

Research output: Contribution to journalArticle

Mangioni, Costantino ; Bolis, Giorgio ; Natale, Nicola ; Morasca, Luciano. / Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer. In: European Journal of Cancer (1965). 1976 ; Vol. 12, No. 5. pp. 353-356.
@article{119ec0bcc14549939e4f01ba82e74b27,
title = "Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer",
abstract = "A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented M{\"u}llerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.",
author = "Costantino Mangioni and Giorgio Bolis and Nicola Natale and Luciano Morasca",
year = "1976",
doi = "10.1016/0014-2964(76)90172-9",
language = "English",
volume = "12",
pages = "353--356",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer

AU - Mangioni, Costantino

AU - Bolis, Giorgio

AU - Natale, Nicola

AU - Morasca, Luciano

PY - 1976

Y1 - 1976

N2 - A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented Müllerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.

AB - A low dose, continuous treatment by cyclophosphamide (100 mg/day p.o.) has been given to 141 patients with documented Müllerian ovarian cancer. From this total 134 have been evaluated for drug related toxicity. Response and survival have been studied in 72 patients in stages III, IV or in recurrence, all with at least one measurable tumor mass. Results demonstrate that this regimen of administration induces remission and prolongation of median survival with a very low level of toxicity and minimal discomfort to the patient.

UR - http://www.scopus.com/inward/record.url?scp=0017124913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017124913&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(76)90172-9

DO - 10.1016/0014-2964(76)90172-9

M3 - Article

C2 - 954793

AN - SCOPUS:0017124913

VL - 12

SP - 353

EP - 356

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 5

ER -